Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a fiber from agave help tame type 2 diabetes?

NCT ID NCT07696247

Disease control Sponsor: Universidad Autonoma de Queretaro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests whether taking agave inulin, a natural fiber, for eight weeks can improve blood sugar control and increase healthy gut bacteria in adults with type 2 diabetes. Participants receive either 10 grams of agave inulin or a placebo daily. Researchers measure changes in blood sugar, insulin resistance, and gut microbes to see if this simple supplement offers metabolic benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
agave inulin
What this could lead to
If it works, this could point toward a simple dietary supplement to help manage blood sugar and support beneficial gut bacteria in people with type 2 diabetes.
What could go wrong
This is a small, early-stage trial with only 43 participants, so results may not apply broadly. The supplement may cause digestive discomfort and might not improve diabetes control significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

43 people

The number who actually took part.

Started

Apr 2024

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Confirmed diagnosis of type 2 diabetes mellitus. * Age between 20 and 75 years. * Residence in Querétaro, Mexico. * Stable oral hypoglycemic treatment and/or basal insulin. * Ability to provide informed consent. Exclusion Criteria: * HbA1c \> 9.5%. * Current use of probiotics, prebiotics, synbiotics, or fiber supplements within the previous 3 months. * Use of alpha-glucosidase inhibitors. * Severe cardiovascular disease. * Chronic kidney disease stage 3b or higher. * Active gastrointestinal disease. * Pregnancy or lactation. * Known allergy to agave or fructans.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gut microbiota are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome Insulin Resistance metabolic syndrome X type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gut microbiota Insulin resistance Metabolic syndrome Prebiotic Type 2 diabetes

Contacts and locations

Locations

  • Facultad de Ciencias Naturales, Campus Juriquilla

    Querétaro City, Querétaro, 76230, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.